…
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ImmunoPrecise Antibodies Ltd provides antibody discovery, development and reagent services to pharmaceutical, biotech and academic customers. Long-term growth may be supported by secular outsourcing of biologics R&D, rising demand for therapeutic and diagnostic antibodies, and expansion of partnerships and platform capabilities, which could make it an attractive way to access biologics services.
Key investment risks include competitive pressure from larger CROs, sensitivity to pharmaceutical R&D spending cycles, execution and integration risks from growth, and potential financial volatility given the company's small-cap profile.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| HYFT MindWalk Holdings Corp. |
- -% |
1.03 | - | - | - | - |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.